APRE

Aprea Therapeutics, Inc.

0.80 USD

Last updated Sep 4, 20:03 UTC

Yesterday HIGH

$0.82

Yesterday LOW

$0.78

52w HIGH

$1.69

52w LOW

$0.55

EPS

-0.07

PE

-11.43

Next Earnings

Nov 11, 2026

Overview News Government Trades Fundamentals

Aprea Therapeutics, Inc. stock is up 29.08% since 30 days ago. The next earnings date is Nov 11, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Newsdesk

Thu Jul 30, 2026

Aprea Therapeutics Announces ACESOT-1051 Enrollment Is Accelerating; Clinical Data Presentation Planned For Q4 2026

Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with
Benzinga Newsdesk

Mon Jun 1, 2026

Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors

Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined
Benzinga Newsdesk

Thu May 14, 2026

Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $7 to $6.
Benzinga Insights

Wed May 13, 2026

Earnings Scheduled For May 13, 2026
Benzinga Newsdesk

Wed May 13, 2026

Aprea Therapeutics Q1 EPS $(0.22) Beats $(0.23) Estimate

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.35 percent. This is a 66.67 percent increase over losses of $(0.66) per share from
Avi Kapoor

Thu May 7, 2026

This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts view APRE, SRFM, CNH stocks.
Benzinga Newsdesk

Thu May 7, 2026

Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

Oppenheimer analyst Matthew Biegler initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Outperform rating and announces Price Target of $5.
Benzinga Insights

Mon May 4, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Newsdesk

Tue Apr 21, 2026

Aprea Therapeutics To Present Abstract Titled 'Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)' At 2026 American Society Of Clinical Oncology Annual Meeting

Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined
Benzinga Insights

Fri Apr 17, 2026

10 Health Care Stocks Moving In Friday's Intraday Session